Latest NAMSW ETF News Today | Earnings, Events & Price Alerts

NAMSW News

NEWAMSTERDAM PHARMA ANNOUNCES INDUCEMENT GRANTS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4)

May 01 2026moomoo

NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)

Mar 06 2026moomoo

NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)

Feb 06 2026moomoo

Insider at NewAmsterdam Pharma (NAMS.US) Plans to Sell $6.33 Million in Common Stock via Form 144

Jan 20 2026moomoo

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 30 2025Newsfilter

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 09 2025Newsfilter

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 27 2025Newsfilter

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 08 2025Newsfilter

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 07 2025Newsfilter

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02 2025Yahoo Finance

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 04 2025Yahoo Finance

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31 2025Yahoo Finance

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

Jan 10 2025Newsfilter

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13 2024Newsfilter

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 12 2024Newsfilter

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10 2024Newsfilter

NAMSW

NAMSW

NAMSW News

NEWAMSTERDAM PHARMA ANNOUNCES INDUCEMENT GRANTS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4)

NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)

NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)

Insider at NewAmsterdam Pharma (NAMS.US) Plans to Sell $6.33 Million in Common Stock via Form 144

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer&#39;s Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma Announces Positive Topline Alzheimer&#39;s Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters&#39; Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares